<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215501</url>
  </required_header>
  <id_info>
    <org_study_id>01-042</org_study_id>
    <nct_id>NCT00215501</nct_id>
  </id_info>
  <brief_title>Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies</brief_title>
  <official_title>A Phase I Trial of Capecitabine or Continuous Infusion 5-Fluorouracil in Combination With Weekly Irinotecan and Cisplatin in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of irinotecan and cisplatin in combination&#xD;
      with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good&#xD;
      and bad) these have on patients with unresectable, advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a Phase I dose escalation study. The dose of drug the patient receives will be&#xD;
           assigned based upon when they enter the study. Since we are looking for the highest dose&#xD;
           of capecitabine or 5-fluorouracil that can be given safely in combination with cisplatin&#xD;
           and irinotecan, not everyone who participates in this study will be receiving the same&#xD;
           amount of the drug.&#xD;
&#xD;
        -  There are four parts to this study: 1)Choice of treatment, 2)Evaluation, 3)Chemotherapy&#xD;
           and 4)Follow-up.&#xD;
&#xD;
        -  The patient and the patient's doctor will decide which form of chemotherapy is best for&#xD;
           the patient, either pill form or continuous infusion. Chemotherapy pills (capecitabine)&#xD;
           are given twice per day for 14 days is a row every 3 weeks. Continuous infusion&#xD;
           (5-fluorouracil) is given through a pump 24 hours a day for 14 days every 3 weeks.&#xD;
&#xD;
        -  Prior to initiation to therapy the extent of the patients cancer will be evaluated. This&#xD;
           includes a CT scan, chest x-ray, EKG and bloodwork.&#xD;
&#xD;
        -  Patient's will receive chemotherapy for 2 weeks followed by a one week break. This will&#xD;
           constitute one cycle. The medications cisplatin and irinotecan will be given&#xD;
           intravenously on the 1st and 8th day of each cycle. Following the rest period the next&#xD;
           cycle of chemotherapy begins.&#xD;
&#xD;
        -  Following 2 cycles of chemotherapy, the patients cancer will be re-evaluated. A CT scan&#xD;
           and bloodwork will be obtained and will be compared to the previous studies. Treatment&#xD;
           will resume if the cancer is the same size or smaller than before and the patient is&#xD;
           tolerating the chemotherapy well. The cancer will be re-evaluated every 2 cycles of&#xD;
           chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To make a preliminary assessment of the anti-tumor activity of these combinations.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-fluorouracil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Orally twice a day for 14 days (dosage will vary)</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <description>Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenously weekly for 2 weeks followed by a one week rest period</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor malignancy&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Two prior chemotherapy regimens for metastatic disease. Prior chemotherapy must have&#xD;
             been completed at least 3 weeks prior to initiation of this protocol.&#xD;
&#xD;
          -  ECOG performance status of 0,1 or 2&#xD;
&#xD;
          -  Neutrophils greater or equal to 1,500/ul&#xD;
&#xD;
          -  Platelets greater or equal to 100,000/ul&#xD;
&#xD;
          -  Serum bilirubin less or equal to 1.5 mg/dl&#xD;
&#xD;
          -  Creatinine clearance greater than 50 ml/min&#xD;
&#xD;
          -  AST or SGOT less or equl to 3x ULN&#xD;
&#xD;
          -  Prior radiotherapy is allowable, provided at least 4 weeks have elapsed and the&#xD;
             patient has recovered from all therapy related side effects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than 3 months&#xD;
&#xD;
          -  Clinically significant cardiac disease or myocardial infarction within past 6 months&#xD;
&#xD;
          -  Suspicion or documentation of CNS metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Psychiatric disability judged by the investigator to be clinically significant,&#xD;
             precluding informed consent&#xD;
&#xD;
          -  Known existing coagulopathy and/or requires therapeutic anticoagulants&#xD;
&#xD;
          -  Uncontrolled diarrhea&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Major surgery within 3 weeks of the state of the study treatment without complete&#xD;
             recovery&#xD;
&#xD;
          -  Serious, uncontrolled, concurrent infection&#xD;
&#xD;
          -  Lack of physical integrity of upper gastrointestinal tract or malabsorption syndrome&#xD;
&#xD;
          -  Prior severe reaction to fluoropyrimidine, irinotecan or cisplatin&#xD;
&#xD;
          -  Known interstitial pulmonary fibrosis&#xD;
&#xD;
          -  Known Gilbert's disease&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Organ allograft(s) on immunosuppressive therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients taking valproic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter C. Enzinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter C. Enzinger, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>advanced solid tumor malignancy</keyword>
  <keyword>capecitabine</keyword>
  <keyword>continuous infusion</keyword>
  <keyword>5-FU</keyword>
  <keyword>irinotecan</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

